标普和纳斯达克内在价值 联系我们

Timber Pharmaceuticals, Inc. TMBR NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
19/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Timber Pharmaceuticals, Inc. (TMBR) .

本页证实的标准:

  • VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分: 18/100 其中 0/7 项标准通过。

SharesGrow 7-Criteria Score
19/100
SG Score
View full scorecard →
价值
N/A
No coverage
未來
20/100
Analyst consensus
→ Forecast
过去
0/100
→ Income
~
健康
67/100
Debt-to-Equity & liquidity
→ Health
护城河
0/100
→ Income
成长
15/100
→ Income
收入
10/100
→ Income

估值概览 — TMBR

估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率8.68
EV/EBITDA0.0
每股数据
EPS (TTM)$-9.19
每股账面价值$0.00
每股营收$0.04
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%

EPS:实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year EPS(稀释) 营收 净利润 净利润率
2013 $-0.01 $0.00 $-52.3K -
2014 $0.00 $0.00 $0.00 -
2015 $-13,030.90 $64K $-15.6M -24371.9%
2016 $-7,710.93 $100K $-18.41M -18406%
2017 $-1,567.94 $73K $-8.98M -12298.6%
2018 $-1,340.11 $57K $-17.26M -30277.2%
2019 $-29.31 $324.65K $-3.69M -1136.7%
2020 $-48.15 $453.81K $-15.12M -3331.3%
2021 $-13.15 $295.74K $-10.64M -3597.5%
2022 $-9.19 $83.18K $-19.38M -23299%
联系我们
🎓
SharesGrow 学院
学习如何计算内在价值,发现被低估的股票。
每周在线课程
给我们留言